Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 3, 2008, Pages 212-218

  Erden, G ^a,b   Barazi, A O ^a   Tezcan, G ^a   Yildirimkaya, M M ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA NUMUNE HOSPITAL   (Turkey)

Author keywords

AFP; Analytical variation; Biological variation; CA 19 9; CEA; Index of individuality; Reference change value

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ANALYTICAL PARAMETERS; ANALYZER; ARTICLE; BLOOD CHEMISTRY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; STATISTICAL SIGNIFICANCE; TUMOR DIAGNOSIS; VOLUNTEER;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 43049116116     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701601699     Document Type: Article

References (32)

1. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002;48:1151-9.
2. Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff JL. Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, editors. Tumor markers. Physiology, pathobiology, technology and clinical applications. 1st edn. Washington, D.C.: AACC Press. 2002. p. 33-63.
3. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52:345-51.
4. Tuxen MK, Söletormos G, Petersen PH, Schioler V, Dombernowsky P. Assessment of biological variation and analytical imprecision of CA 125, CEA and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol 1999;74:12-22.
5. Vastag B. Testicular cancer seen as 'stalking horse' for other cancers. J Natl Cancer Inst 1999;91:1801-3.
6. International germ cell cancer collaborative group (IGCCCG). International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
7. Gold P, Freedman SO. Specific carcinoembryonic antigen of human digestive system. J Exp Med 1965;122:467-81.
8. Tsavaris N, Vonorta K, Tsoutsos H, Kozatsani-Halividi D, Mylonakis N, Papagrigorion D, et al. Carcinoembryonic antigen (CEA), alpha-fetoprotein, CA 19-9 and CA 125 in advanced colorectal cancer (ACC). Int J Biol Markers 1993;8:88-93.
9. Chevinsky AH. CEA in tumors of other than colorectal origin. Semin Surg Oncol 1991;7:162-6.
10. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439-62.
11. Garcia M, Seigner C, Bastid C, Choux R, Payan MJ, Reggio H. Carcinoembryonic antigen has a different molecular weight in normal colon and in cancer cells due to N-glycosylation differences. Cancer Res 1991;51:5679-86.
12. Duk JM, Aalders JG, Fleuren GJ, De Bruijn HWA. CA 125: A useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;155:1097-102.
13. Passerini R, Riggio D, Salvatici M, Zorzino L, Racide D, Sandri MT. Clin Chem Lab Med 2007;45:100-4.
14. Steinberg W. The clinical utility of the CA 19-9 tumor associated antigen. Am J Gastroenterol 1990;85:350-5.
15. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994;69:515-19.
16. Fraser CG, Hyltoft Petersen P, Larsen ML. Setting analytical goals for random analytical errror in specific clinical monitoring situations. Clin Chem 1990;36:1625-8.
17. Harris EK. Effects of intra- and interindividual variation on the appropriate use of normal intervals. Clin Chem 1974;20:1535-42.
18. Fraser CG. Desirable performance standards for clinical chemistry tests. Adv Clin Chem 1983;23:299-339.
19. Talwar DK, Azharuddin MK, Williamson C, Teoh YP, McMillan DC, O'Reilly DSJ. Biological variation of vitamins in blood of healthy individuals. Clin Chem 2005;51:2145-50.
20. Westgard JO, Groth T. Design and evaluation of statistical control procedures: application of a computer 'quality control simulator' program. Clin Chem 1981;27:1536-45.
21. Yildirimkaya MM, Bilgi C, Ozata M, Nazaroglu NK, Gundogan MA. Biological variation of serum lipids and lipoproteins in patients with clinically well controlled non insulin dependent diabetes mellitus. Endocrine J 1996;43:345-51.
22. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
23. Soletormos G, Nielsen D, Schioler V, Mouridssen H, Dombernowsky P. Monitoring different stages of breast cancer using tumor markers CA 15-3, CEA and TPA. Eur J Cancer 2004;40:481-6.
24. Soletormos G, Schioler V, Nielsen D, Skovsgaard T, Dombernowsky P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 1993;39:2077-83.
25. Fraser CG, editors. Biological variation: from principles to practice. Washington, D.C.: AACC Press. 2001. p. 67-90.
26. Fraser CG. Inherent biological variation and reference values. Clin Chem Lab Med 2004;42:758-64.
27. Berek JS, Bertelsen K, Du Bois A, Brady MF, Carmichael J, Eisenhauer EA, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999;10:S87-92.
28. Plebani M, Giacomini A, Beghi L, de Paoli M, Roveroni G, Galeotti F, et al. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res 1996;16:2249-52.
29. Browning MCK, McFarlane NP. Objective interpretation of results for tumor markers. J Nucl Med Allied 1990;34:89-91.
30. Vestergaard EM, Hein HO, Meyer., Grunnet N, Jorgensen J, Wolf H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different lewis and secretor genotypes and evaluation of secretor and lewis genotyping in a Caucasian population. Clin Chem 1999;45:54-61.
31. Trape J, Botargues JM, Porta F, Ricos C, Badal JM, Salinas R, et al. Reference change value for alpha-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. Clin Chem 2003;7:1209-11.
32. Christiansen M, Høgdall CK, Andersen JR, Nørgaard-Pedersen B. Alpha-fetoprotein in plasma and serum of healthy adults: preanalytical, analytical and biological sources of variation and construction of age-dependent reference intervals. Scand J Clin Lab Invest 2001;61:205-15.